William L. Warren

Sutherland
Lawyer (Partner)

Bill Warren, a partner in Sutherland’s Intellectual Property Practice Group and chair of the firm’s Life Sciences Team, focuses his practice on patent counseling related to biotech, medical device and pharmaceutical inventions, but also handles a wide variety of other technologies. For more than two decades, he has worked with clients ranging from multinational corporations, to early-stage entrepreneurial companies, to nonprofit university and science research centers.

A significant portion of Bill’s practice includes prosecuting patents, counseling clients on patent validity and infringement issues, and preparing product clearance opinions and development strategies. He also negotiates technology transfer licensing agreements and conducts intellectual property due diligence. Bill also protects trademarks and copyrights and, when necessary, participates in litigating intellectual property issues. In particular, Bill’s practice involves counseling various entities on Hatch-Waxman generic pharmaceutical and biosimilars legal issues.

Bill provides leadership to Sutherland’s Life Sciences Team, the majority of whose members also have graduate degrees in the life sciences. Bill serves as a frequent speaker and author on developments in intellectual property law, particularly those affecting the life sciences industry. In addition to his law degree, Bill holds an MBA and a Master of Science degree in Molecular Genetics.

Bill is registered to practice before the U.S. Patent and Trademark Office.

Linked author

Hill, Kertscher & Wharton (Atlanta)

Articles

263 Bulletin

John L. North, William L. Warren A U.S. Court of Appeals holds that antitrust law is not implicated provided that the terms of “pay for delay” settlements between the brand name and generic pharma companies are within the scope of the patent (Valley Drug/Abbott Laboratories)

263

A recent 11th Circuit case, Valley Drug Co. v. Geneva Pharmaceuticals, Inc., sheds light on the complex intersection of patent and antitrust law in the context of a settlement agreement between a name brand pharmaceutical manufacturer and two allegedly infringing generic manufacturers that (...)

Send a message